Clinical Trials Browser

Phase 3 × lenvatinib × Genitourinary × Clear all

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04736706 2026-05-06

MK-6482-012

Phase 3 Active not recruiting

1,653 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04586231 2026-05-05

MK-6482-011

Phase 3 Active not recruiting

747 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Genitourinary

Carcinoma, Renal Cell

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Phase 3 Not yet recruiting

718 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Phase 3 Active not recruiting

249 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

1,250 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Clinical Trials

MK-6482-043

MK-6482-012

MK-6482-011

CLEAR

LEAP-011

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

CARE1